Translating discoveries into medicine: psychiatric drug development in 2011.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Emotion and Theory of Mind in Schizophrenia-Investigating the Role of the Cerebellum.Cerebellum (London, England) · 2016
   Pooled it
2. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.Nature medicine · 2020
   Trial
3. PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.CNS drugs · 2014
   Trial
4. Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trial.Communications medicine · 2026
   Article
5. A Framework for Advancing Mechanistic Neurobehavioral Biomarkers in Psychiatry.Biological psychiatry · 2026
   Review
6. Challenges for switching central nervous system and psychiatric medication products: A review of the literature.Journal of psychopharmacology (Oxford, England) · 2025
   Review
7. Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial.Journal of neural transmission (Vienna, Austria : 1996) · 2023
   Article
8. Experimental Medicine Approaches in Early-Phase CNS Drug Development.Advances in neurobiology · 2023
   Article
9. Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial.Contemporary clinical trials communications · 2020
   Article
10. Improved Scalability of Neuron-Based Phenotypic Screening Assays for Therapeutic Discovery in Neuropsychiatric Disorders.Molecular neuropsychiatry · 2018
    Article
11. Facilitating the commercialization and use of organ platforms generated by the microphysiological systems (Tissue Chip) program through public-private partnerships.Computational and structural biotechnology journal · 2016
    Review
12. Future directions for research in autism spectrum disorders.Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53 · 2014
    Article
13. Innovation in therapeutics development at the NCATS.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014
    Article
14. Quest for biomarkers of treatment-resistant depression: shifting the paradigm toward risk.Frontiers in psychiatry · 2013
    Article
15. The research domain criteria framework in drug discovery for neuropsychiatric diseases: focus on negative valence.Brain and neuroscience advances
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as